ABCL - AbCellera and Empirico ink strategic multi-target antibody discovery collaboration

AbCellera (ABCL) and Empirico announce that they have entered into a strategic multi-target discovery collaboration to develop and commercialize novel antibodies.Empirico will use its Precision Insights Platform, a human genetics-focused discovery platform, to select up to five therapeutic targets.AbCellera will use its AI-powered antibody discovery technology to search and analyze natural immune responses to identify antibodies with the desired therapeutic properties against the selected targets.Under the terms of the agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration.AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico.

For further details see:

AbCellera and Empirico ink strategic multi-target antibody discovery collaboration